CS
Kuros Biosciences AG
CSBTF · OTC
$24.00 +0.00% (+$0.00)
1M +9.09%
Market Cap CHF 785.3M
P/E Ratio 370.51x
Div. Yield -
ROE 3.09%
Bulios Fair Price
$19.38
19.3% downside
Current Price
$24
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CSBTF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
3 /100
Expensive EV/EBITDA 76.35x
P/S 6.47x
P/B 11.73x
Growth
82 /100
Growing Book val. growth 0.93%
Rev. growth 88.96%
FCF growth N/A
Profitability
31 /100
Weak Net margin 1.75%
Op. margin 6.04%
FCF margin 1.98%
Quality
30 /100
Poor ROE 3.09%
ROA 1.98%
Asset turnover 1.13x
Debt
100 /100
Low Current ratio 1.96x
Int. coverage 24.04x
Net debt/EBITDA -1.16x
Stability
39 /100
Moderate Rev. volatility 32.44%
EPS volatility 69.95%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CSBTF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Christopher T. Fair
Employees
178
Headquarters
Schlieren
Upcoming events
17 MAR
Earnings
Upcoming earnings report